| |
Large-scale. Long-term. Maintenance studies in major depressive disorder are broad in scope, duration, and size. Build your optimal study plan and mitigate risk with the help of our guide. Learn more. .png)
|
|
Today’s Big NewsOct 11, 2024 |
|
The deal will help Jubilant Biosys expand its footprints in Europe for drug discovery and pre-clinical offerings in areas like biologics and ADC on top of existing integrated drug discovery services & CDMO from India. 
|
|
| By James Waldron The U.S. drugmaker has “mutually agreed” to terminate its collaboration and license agreement with South Korean biotech Yuhan for a pair of MASH therapies. |
|
|
|
By Gabrielle Masson Difficult. Impossible. Agonizing. Worse than voting in the national election. All those descriptors were used today by FDA advisory committee members when asked to vote on an investigational rare disease therapy. |
By James Waldron Turnstone Biologics is reducing its headcount by 60% and shaking up its C-suite in order to keep the cash flowing to its sole clinical-stage candidate. |
By James Waldron Upstream Bio has swollen its IPO to $255 million as the company joins CAMP4 Therapeutics this morning in becoming the latest biotechs to list on the Nasdaq. |
|
When the world is changing, you need a global CDMO with a strong global presence to protect your molecule. Our team of experts help progress any molecule type, however complex, from pre-clinical to commercial. Learn more about our tech transfer capabilities. 
|
|
By Nick Paul Taylor Sanofi has stopped a phase 2 trial of the Denali Therapeutics-partnered oditrasertib in multiple sclerosis. The French drugmaker tore the RIPK1 inhibitor trial from its list of active studies after failing to meet its primary and secondary endpoints, dealing a further blow to a collaboration with a troubled history. |
By Gabrielle Masson Alaunos Therapeutics is axing an agreement with Precigen, giving up licensing rights to a personalized T-cell platform. |
By Darren Incorvaia Capricor Therapeutics is taking a victory lap for their phase 2 Duchenne muscular dystrophy (DMD) trial. At 3 years, the San Diego-based company’s cell therapy deramiocel improved patients’ left ventricular ejection fraction and ability to use their upper limbs. |
By Darren Incorvaia,Zoey Becker Eli Lilly is ramping up its efforts to incorporate AI across its business by appointing Thomas Fuchs to the new role of chief AI officer. In his new job, Fuchs will lead AI initiatives across Lilly’s drug discovery, clinical trials, manufacturing, commercial activities and internal functions. |
By Zoey Becker After initially supporting a meeting with activist investor Starboard Value, Pfizer's former CEO and CFO publicly changed their tune after being threatened with litigation by Pfizer, Starboard alleges. |
By Darren Incorvaia To find RNA viruses hiding in genomic “dark matter,” researchers took advantage of one thing they all have in common: the RNA polymerase enzyme. |
By Angus Liu As Roche comes under competitive pressure on its breast cancer business, the Swiss company hopes a new drug will add a 2-billion-Swiss-francs luster to the once high-flying portfolio. |
By Angus Liu AstraZeneca has bagged a cardiovascular disease candidate from China's CSPC Pharma in a deal potentially worth $2 billion. Astellas is shuffling its cell therapy research team and investing in a dementia gene therapy candidate. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma's Fraiser Kansteiner chats with industry leaders about the surge in neuroscience investment, breakthroughs and future targets in neuropharmaceuticals. |
|
|---|
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
